Rationality of routine clinical use of olokizumab in COVID-19
https://doi.org/10.37489/2588-0519-2020-S4-68-70
Abstract
Routine clinical use of olokizumab in COVID-19 is not recommended. The use of olokizumab is possible in clinical trials.
About the Authors
V. M. Tsvetov
Federal Center for Cardiovascular Surgery of the Ministry of Health of Russia
Russian Federation
Russian Federation
Tsvetov Vitaly M. – Candidate of Medical Sciences, Doctor — Clinical Pharmacologist. SPIN code: 3202-7659
Chelyabinsk
A. V. Matveev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. State register of medicines (In Russ). Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=944a84ad-c40d-4964ae4d-f2c913a26400&t= Ссылка активна на 28.05.2020
2. U.S. Pharmacopeia [Internet]. [cited 28.05.2020]; Available from: https://www.usp.org/
3. E.U. Pharmacopeia [Internet]. [cited 28.05.2020]; Available from: https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-10th-edition
4. https://clinicaltrials.gov/ct2/show/NCT04380519?cond=Olokizumab&draw=2&rank=7
5. Russell B, Moss C, George G et al. Associations between immunesuppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020 Mar 27;14:1022. DOI: 10.3332/ecancer.2020.1022
6. Choy EH, De Benedetti F, Takeuchi T et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020 Jun;16(6):335-345. DOI: 10.1038/s41584-020-0419-z
7. Magro G. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X. 2020 Jun;2(2):100029. DOI: 10.1016/j.cytox.2020.100029
8. Temporary guidelines of the Ministry of health of the Russian Federation. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) (In Russ). Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_%D0%9CR_COVID-19_v6.pdf Ссылка активна на 28.05.2020
Review
For citations:
Tsvetov V.M., Matveev A.V., Sychev D.A. Rationality of routine clinical use of olokizumab in COVID-19. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):68-70. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-68-70
Views:
5730
Email this article 